13,14-Dihydro-15-keto-prostaglandin F2 alpha in patients with urogenital tumors.

Authors :: Dunzendorfer U
Zahradnik HP
Gerster K
Source :: Urologia internationalis [Urol Int] 1980; Vol. 35 (3), pp. 171-5.
Publication Year :: 1980
Abstract: 13,14-Dihydro-15-keto-prostaglandin F2 alpha (13,14-DHK-PGF2 alpha) represents a stable product of degradation after pulmonary flow and it is shown to be reliably measured by radioimmunoassay. In patients with urogenital tumors, serum levels of 13,14-DHK-PGF2 alpha are distinctly elevated when compared to a control group. The rate of synthesis of this compound in urogenital tumors, however, appears to be different.

Subjects :: Adenocarcinoma blood
Female
Humans
Kidney Neoplasms blood
Male
Neoplasms, Germ Cell and Embryonal blood
Prostatic Hyperplasia blood
Prostatic Neoplasms blood
Radioimmunoassay
Testicular Neoplasms blood
Urinary Bladder Neoplasms blood
Dinoprost analogs & derivatives
Prostaglandins F blood
Urogenital Neoplasms blood

Full Text Access

Tools